These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 2093302

  • 21. Oral estramustine therapy in serum chromogranin A-positive stage D3 prostate cancer patients.
    Zaky Ahel M, Kovacic K, Kraljic I, Tarle M.
    Anticancer Res; 2001; 21(2B):1475-9. PubMed ID: 11396235
    [Abstract] [Full Text] [Related]

  • 22. Hormonal predictors of prostate cancer.
    Sofikerim M, Eskicorapci S, Oruç O, Ozen H.
    Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
    [Abstract] [Full Text] [Related]

  • 23. [Testosterone, albumin and sex steroid-binding globulin in the blood serum of patients with laryngeal cancer].
    Kushlinskiĭ NE, Bassalyk LS, Alferov VS, Ogol'tsova ES, Savinskaia AP.
    Vopr Onkol; 1985; 31(8):36-41. PubMed ID: 4041091
    [Abstract] [Full Text] [Related]

  • 24. Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma.
    Vaughn DJ, Brown AW, Harker WG, Huh S, Miller L, Rinaldi D, Kabbinavar F.
    Cancer; 2004 Feb 15; 100(4):746-50. PubMed ID: 14770430
    [Abstract] [Full Text] [Related]

  • 25. Intermittent complete androgen blockade in metastatic prostate cancer.
    Rambeaud JJ.
    Eur Urol; 1999 Feb 15; 35 Suppl 1():32-6. PubMed ID: 10081701
    [Abstract] [Full Text] [Related]

  • 26. Chronic hepatitis C infection and sex hormone levels: effect of disease severity and recombinant interferon-alpha therapy.
    Nguyen HV, Mollison LC, Taylor TW, Chubb SA, Yeap BB.
    Intern Med J; 2006 Jun 15; 36(6):362-6. PubMed ID: 16732861
    [Abstract] [Full Text] [Related]

  • 27. Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer.
    Noguchi M, Itoh K, Suekane S, Morinaga A, Sukehiro A, Suetsugu N, Katagiri K, Yamada A, Noda S.
    Prostate; 2004 Jun 15; 60(1):32-45. PubMed ID: 15129427
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Effect of estramustine phosphate on plasma testosterone during treatment of carcinoma of prostate.
    Kjaer TB, Nilsson T, Madsen PO.
    Urology; 1975 Jun 15; 5(6):802-4. PubMed ID: 1136096
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Hormone changes in patients with prostatic carcinoma during treatment with estramustine phosphate.
    Fosså SD, Fosså J, Aakvaag A.
    J Urol; 1977 Dec 15; 118(6):1013-8. PubMed ID: 926240
    [Abstract] [Full Text] [Related]

  • 37. Effect of orchidectomy on serum concentrations of testosterone and dihydrotestosterone in patients with prostatic cancer.
    Røhl HF, Beuke HP.
    Scand J Urol Nephrol; 1992 Dec 15; 26(1):11-4. PubMed ID: 1631501
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Immediate estrogen or estramustine phosphate therapy versus deferred endocrine treatment in nonmetastatic prostate cancer: a randomized multicenter study with 15 years of followup. The South Sweden Prostate Cancer Study Group.
    Lundgren R, Nordle O, Josefsson K.
    J Urol; 1995 May 15; 153(5):1580-6. PubMed ID: 7714978
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.